...
首页> 外文期刊>Thoracic cancer. >Analysis for the mechanism between the small cell lung cancer and non‐small cell lung cancer combing the miRNA and mRNA expression profiles
【24h】

Analysis for the mechanism between the small cell lung cancer and non‐small cell lung cancer combing the miRNA and mRNA expression profiles

机译:结合miRNA和mRNA表达谱分析小细胞肺癌和非小细胞肺癌的机制

获取原文
   

获取外文期刊封面封底 >>

       

摘要

AbstractBackgroundWe investigated the relationship between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on micro ribonucleic acid (miRNA) and messenger (m)RNA expression profiles.MethodsUtilizing the differentially expressed mRNAs and the targeting miRNAs, the mRNA-miRNA network for the two cancers was constructed. By integrating the miRNA expression profile, drug, and drug targets, miRNA-drug target-drug networks were established and the mechanisms in drug therapy efficacy were compared between SCLC and NSCLC.ResultsDrug targets of different expressed miRNAs of SCLC are mainly located in the organelle, act in the electron carrier activity, and consist of the synapse; while drug targets of NSCLC are the membrane-enclosed lumen, mainly distributed in the extracellular region and synapse, and function in the binding. Drug targets of miRNA expressed commonly in the two cancers are involved in the reproduction multi-organism process. In SCLC, the miR-16 in the miRNA-drug target-drug network is significant and follows the result of the mRNA-miRNA network. The pigmentation and rhythmic process of SCLC is different from NSCLC, while the process of cellular component biogenesis and cellular component organization are important for the occurrence of NSCLC. miR-16 in the miRNA-mRNA-drug network of SCLC is significant and we acquired 11 potential drugs, such as dexamethasone and budesonide. The miR-124 for NSCLC is important in the network and 17 potential drugs were screened, including dexamethasone and budesonide.ConclusionsThese findings suggest that miR-16 and miR-124 might be novel diagnostic and prognostics markers for SCLC and NSCLC, respectively.
机译:摘要背景:我们基于微核糖核酸(miRNA)和信使(m)RNA表达谱研究了小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC)的关系。方法利用差异表达的mRNA和靶向miRNA,构建了两种癌症的mRNA-miRNA网络。通过整合miRNA的表达谱,药物和药物靶标,建立了miRNA-药物靶标-药物网络,比较了SCLC和NSCLC的药物疗效机制。 ,起电子载流子的作用,并由突触组成; NSCLC的药物靶点是膜封闭腔,主要分布在细胞外区域和突触中,并在结合中起作用。在这两种癌症中普遍表达的miRNA的药物靶标参与了繁殖多菌体的过程。在SCLC中,miRNA-药物靶标-药物网络中的miR-16非常重要,并且遵循mRNA-miRNA网络的结果。 SCLC的色素沉着和节律过程不同于NSCLC,而细胞成分的生物发生和细胞成分的组织过程对于NSCLC的发生很重要。 SCLC的miRNA-mRNA-药物网络中的miR-16具有重要意义,我们获得了11种潜在药物,例如地塞米松和布地奈德。 NSCLC的miR-124在网络中很重要,筛选了17种潜在药物,包括地塞米松和布地奈德。结论这些发现表明miR-16和miR-124可能分别是SCLC和NSCLC的新型诊断和预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号